We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.2B
AUM Growth
+$1.75B
Cap. Flow
+$1.1B
Cap. Flow %
6.8%
Top 10 Hldgs %
54.17%
Holding
115
New
28
Increased
36
Reduced
22
Closed
20

Top Buys

Rank Stock Value
1
AABA
Altaba Inc
AABA
+$784M
2
ESRX
Express Scripts Holding Company
ESRX
+$504M
3
GD icon
General Dynamics
GD
+$348M
4
XL
XL Group Ltd.
XL
+$329M
5
KDP icon
Keurig Dr Pepper
KDP
+$194M

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$618M
2
MON
Monsanto Co
MON
+$543M
3
COL
Rockwell Collins
COL
+$151M
4
ABLX
Ablynx NV
ABLX
+$134M
5
PPLI
People Inc
PPLI
+$112M

Sector Composition

Rank Sector Weight
1 Healthcare 20.57%
2 Technology 19.02%
3 Financials 14.39%
4 Communication Services 11.79%
5 Industrials 10.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
51
CRISPR Therapeutics
CRSP
$5.75B
$50.6M 0.31%
860,700
+215,700
+33% +$12.3M
NVCR icon
52
NovoCure
NVCR
$1.99B
$49.8M 0.31%
1,590,000
-260,000
-14% -$7.23M
EVHC
53
DELISTED
Envision Healthcare Holdings Inc
EVHC
$48M 0.3%
1,090,000
+725,000
+199% +$29.8M
CAVM
54
DELISTED
Cavium, Inc.
CAVM
$47.1M 0.29%
545,000
-1,345,000
-71% -$108M
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$31.6B
$40.9M 0.25%
415,000
+45,000
+12% +$4.46M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$36.7M 0.23%
743,500
+473,500
+175% +$17.9M
BUD icon
57
AB InBev
BUD
$155B
$36.1M 0.22%
+358,533
New +$35.6M
RC
58
Ready Capital
RC
$311M
$35.9M 0.22%
2,208,239
– –
HRG
59
DELISTED
HRG Group, Inc.
HRG
$30M 0.19%
2,290,000
-1,750,000
-43% -$23.4M
SVRA icon
60
Savara
SVRA
$1.15B
$25.2M 0.16%
2,225,000
– –
NTLA icon
61
Intellia Therapeutics
NTLA
$1.8B
$23M 0.14%
840,000
+190,000
+29% +$4.6M
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$22M 0.14%
+1,440,000
New +$24.9M
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.3M 0.13%
+2,651,100
New +$20.2M
BMS
64
DELISTED
Bemis
BMS
$18.7M 0.12%
442,500
-120,000
-21% -$5.18M
CDXS icon
65
Codexis
CDXS
$183M
$16.2M 0.1%
+1,125,000
New +$14.7M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$15.1M 0.09%
1,150,000
+200,000
+21% +$2.39M
VYGR icon
67
Voyager Therapeutics
VYGR
$209M
$15M 0.09%
768,157
-121,843
-14% -$2.41M
BLCM
68
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$14.8M 0.09%
+200,000
New +$15.6M
APTX
69
DELISTED
Aptinyx Inc. Common Stock
APTX
$14.4M 0.09%
+596,800
New +$12.8M
AMRN
70
Amarin Corp
AMRN
$298M
$13.9M 0.09%
224,250
-3,750
-2% -$232K
LRMR icon
71
Larimar Therapeutics
LRMR
$434M
$13M 0.08%
+105,545
New +$8.97M
GRFS
72
Grifois
GRFS
$5.44B
$11.9M 0.07%
551,304
+158,500
+40% +$3.46M
CHRS icon
73
Coherus Oncology
CHRS
$219M
$11.8M 0.07%
+845,000
New +$12.1M
SHPG
74
DELISTED
Shire pic
SHPG
$11.7M 0.07%
+69,547
New +$11.2M
ZEAL
75
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$11.4M 0.07%
900,000
+35,000
+4% +$532K
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2018 Portfolio in Review

As of Q2 2018, Thomas Steyer held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Thomas Steyer deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 16% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.

  • Thomas Steyer's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
  • Thomas Steyer added most to Altaba Inc in Q2 2018, an estimated $784M increase.
  • Thomas Steyer's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
  • Thomas Steyer fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
  • Thomas Steyer's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
  • Thomas Steyer opened 28 new positions and closed 20 in Q2 2018.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $16.2B.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.